Gene therapies are revolutionizing the therapeutic landscape for a huge number of diseases. For the field to progress however there are several unique and complex challenges to overcome.
Perhaps the most prominent of these challenges is the immune response to gene therapy delivery.
Immunogenicity stands as one of, in not THE most pressing challenge facing gene therapy drug developers. Neutralising antibodies and their associated immune response currently compromise both the safety and efficacy of delivering gene therapies to vast proportions of the rare disease patient population. As a result, a huge unmet medical need is created by patients unable to receive this revolutionary therapy.
Uniting industry leaders across the gene therapy space this multi-disciplinary forum will enable you to develop more effective and safe gene therapies by:
- Identifying and tailoring novel capsid proteins for more specific targeting
- Reducing AAV neutralizing antibodies
- Confidently assessing immunosuppression strategies to dampen immune response.
How Will it Help You Measure, Modulate and Predict Immunogenicity?
Built specifically for gene therapy drug developers this is the industry’s definitive meeting, developed to unite the field’s experts in order to tackle your biggest immunogenicity roadblocks and enhance your current programs to bring transformative treatments to patients more quickly and efficiently.
Join this meeting to hear 20+ case studies and clinical readouts from experts at the forefront of the gene therapy field. Join the discussion and explore methods of immunogenicity mitigation, bioanalytical assay analysis and standardization, immune response prediction and join the discussion surrounding re-dosing of patients.